GB201517531D0 - Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers - Google Patents

Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

Info

Publication number
GB201517531D0
GB201517531D0 GBGB1517531.8A GB201517531A GB201517531D0 GB 201517531 D0 GB201517531 D0 GB 201517531D0 GB 201517531 A GB201517531 A GB 201517531A GB 201517531 D0 GB201517531 D0 GB 201517531D0
Authority
GB
United Kingdom
Prior art keywords
gdf
inhibitors
combination therapy
immune checkpoint
human growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1517531.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Priority to GBGB1517531.8A priority Critical patent/GB201517531D0/en
Publication of GB201517531D0 publication Critical patent/GB201517531D0/en
Priority to DK16778750.6T priority patent/DK3355919T3/en
Priority to EA201890850A priority patent/EA201890850A1/en
Priority to HRP20221530TT priority patent/HRP20221530T1/en
Priority to KR1020187012421A priority patent/KR20180054868A/en
Priority to HUE16778750A priority patent/HUE060762T2/en
Priority to EP22203233.6A priority patent/EP4218809A3/en
Priority to BR112018006218A priority patent/BR112018006218A2/en
Priority to CN201680071106.8A priority patent/CN108463246A/en
Priority to FIEP16778750.6T priority patent/FI3355919T3/en
Priority to PCT/EP2016/073520 priority patent/WO2017055613A2/en
Priority to PL16778750.6T priority patent/PL3355919T3/en
Priority to SI201631649T priority patent/SI3355919T1/en
Priority to EP16778750.6A priority patent/EP3355919B1/en
Priority to AU2016333539A priority patent/AU2016333539B2/en
Priority to MA43035A priority patent/MA43035B1/en
Priority to CN202410060871.6A priority patent/CN117883572A/en
Priority to JP2018516739A priority patent/JP6925326B2/en
Priority to US15/765,176 priority patent/US11464856B2/en
Priority to CA3000293A priority patent/CA3000293A1/en
Priority to MDE20180766T priority patent/MD3355919T2/en
Priority to LTEPPCT/EP2016/073520T priority patent/LT3355919T/en
Priority to IL299478A priority patent/IL299478A/en
Priority to ES16778750T priority patent/ES2937167T3/en
Priority to PT167787506T priority patent/PT3355919T/en
Priority to IL258393A priority patent/IL258393B2/en
Priority to HK18115128.3A priority patent/HK1256067A1/en
Priority to JP2021123302A priority patent/JP7443298B2/en
Priority to US17/823,383 priority patent/US20230093412A1/en
Priority to AU2023202602A priority patent/AU2023202602A1/en
Priority to JP2024017520A priority patent/JP2024054251A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
GBGB1517531.8A 2015-10-02 2015-10-02 Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers Ceased GB201517531D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GBGB1517531.8A GB201517531D0 (en) 2015-10-02 2015-10-02 Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
PT167787506T PT3355919T (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
AU2016333539A AU2016333539B2 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human Growth and Differentiation Factor 15 (GDF-15) and immune checkpoint blockers
JP2018516739A JP6925326B2 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth differentiation factor 15 (GDF-15) and immune checkpoint blockers
MA43035A MA43035B1 (en) 2015-10-02 2016-09-30 Combination therapy using human differentiation and growth factor 15 (gdf-15) inhibitors and immune checkpoint blockers
KR1020187012421A KR20180054868A (en) 2015-10-02 2016-09-30 Combination therapy with an inhibitor of human proliferation and differentiation factor 15 (GDF-15) and an immune checkpoint blocker
HUE16778750A HUE060762T2 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
EP22203233.6A EP4218809A3 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
BR112018006218A BR112018006218A2 (en) 2015-10-02 2016-09-30 hgdf-15 inhibitors, their uses, composition, kit, combinations and in vitro method for determining whether a substance of interest is an hgdf-15 inhibitor
CN201680071106.8A CN108463246A (en) 2015-10-02 2016-09-30 User's growth and differentiation factor 15 (GDF-15) inhibitor and immunologic test order the combination therapy of blocking agent
FIEP16778750.6T FI3355919T3 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
PCT/EP2016/073520 WO2017055613A2 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
PL16778750.6T PL3355919T3 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
SI201631649T SI3355919T1 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
EP16778750.6A EP3355919B1 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
DK16778750.6T DK3355919T3 (en) 2015-10-02 2016-09-30 COMBINATION THERAPY USING HUMAN GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) INHIBITORS AND IMMUNE CHECKPOINT BLOCKERS
HRP20221530TT HRP20221530T1 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
CN202410060871.6A CN117883572A (en) 2015-10-02 2016-09-30 Human GDF-15 inhibitor, composition and kit containing same and application thereof
ES16778750T ES2937167T3 (en) 2015-10-02 2016-09-30 Combination therapy using human growth and differentiation factor-15 (GDF-15) inhibitors and immune checkpoint blockers
US15/765,176 US11464856B2 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
CA3000293A CA3000293A1 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
MDE20180766T MD3355919T2 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
LTEPPCT/EP2016/073520T LT3355919T (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
IL299478A IL299478A (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
EA201890850A EA201890850A1 (en) 2015-10-02 2016-09-30 COMBINED TREATMENT WITH THE USE OF HUMAN INHIBITORS OF GROWTH AND DIFFERENTIATION 15 (GDF-15) AND IMMUNE RESPONSE CONTROL POINTERS
IL258393A IL258393B2 (en) 2015-10-02 2018-03-27 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
HK18115128.3A HK1256067A1 (en) 2015-10-02 2018-11-27 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
JP2021123302A JP7443298B2 (en) 2015-10-02 2021-07-28 Combination therapy using inhibitors of human growth differentiation factor 15 (GDF-15) and immune checkpoint blockers
US17/823,383 US20230093412A1 (en) 2015-10-02 2022-08-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
AU2023202602A AU2023202602A1 (en) 2015-10-02 2023-04-28 Combination therapy using inhibitors of human Growth and Differentiation factor 15 (GDF-15) and immune checkpoint blockers
JP2024017520A JP2024054251A (en) 2015-10-02 2024-02-07 Combination therapy using an inhibitor of human growth differentiation factor 15 (GDF-15) and an immune checkpoint blocker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1517531.8A GB201517531D0 (en) 2015-10-02 2015-10-02 Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

Publications (1)

Publication Number Publication Date
GB201517531D0 true GB201517531D0 (en) 2015-11-18

Family

ID=54606075

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1517531.8A Ceased GB201517531D0 (en) 2015-10-02 2015-10-02 Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

Country Status (2)

Country Link
GB (1) GB201517531D0 (en)
MA (1) MA43035B1 (en)

Also Published As

Publication number Publication date
MA43035A (en) 2018-08-08
MA43035B1 (en) 2022-12-30

Similar Documents

Publication Publication Date Title
HK1256067A1 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
IL272137A (en) Interleukin-21 muteins and methods of treatment
IL285019A (en) Transponders and sensors for implantable medical devices and methods of use thereof
IL279752B (en) Polycyclic compounds and use thereof in the treatment of immune disorders
IL262831A (en) Medical implants and methods of preparation thereof
IL273918A (en) Trispecific proteins and methods of use
HK1220337A1 (en) Methods and devices related to patient adapted hip joint implants
IL245042A0 (en) Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
GB2519302B (en) Apparatus for artificial cardiac stimulation and method of using the same
EP2967442A4 (en) Systems and methods for treating or supporting human joints or a portion of the human body
HK1250494A1 (en) Biocompatible implants for nerve re-generation and methods of use thereof
EP2961411A4 (en) Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
IL256515A (en) Therapeutic peptides and methods of use thereof
HK1218122A1 (en) Co rti statin analogues for the treatment of inflammatory and or immune diseases
HK1254954A1 (en) Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
HK1249460A1 (en) Implant applicators and methods of administering implants
GB201517531D0 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
GB201607801D0 (en) Combination therapy using inhibitors of human Growth and Differentiation Factor 15 (GDF-15) and immune checkpoint blockers
PL3262069T3 (en) Use of antibodies and antagonists directed against lrg1 in treatment
GB201315231D0 (en) Composition and method for inducing or stimulating growth of keratinous fibres

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)